Risk Factors of Post-transplantation Diabetes Mellitus in Renal Transplant Recipients.
- Author:
Wook Ho KANG
1
;
Myoung Soo KIM
;
Man Ki JU
;
Hye Kyung CHANG
;
Hyung Joon AHN
;
Soon Il KIM
;
Yu Seun KIM
Author Information
1. Department of Surgery, Yonsei University College of Medicine, Seoul, Korea. yukim@yumc.yonsei.ac.kr
- Publication Type:Original Article
- Keywords:
Post-transplantation diabetes mellitus;
Risk factor;
Renal transplantation
- MeSH:
Aged;
Allografts;
Calcineurin;
Diabetes Mellitus*;
Glucose;
Hepatitis B virus;
Humans;
Hyperglycemia;
Incidence;
Kidney Transplantation;
Multivariate Analysis;
Retrospective Studies;
Risk Factors*;
Transplantation*;
Unrelated Donors
- From:The Journal of the Korean Society for Transplantation
2007;21(1):111-118
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: The aim of this study was to assess the incidence of post-transplantation diabetes mellitus (PTDM) in renal allograft recipients and investigate the risk factors contributing to the development and progression of PTDM and its underlying pathogenic mechanism(s). METHODS: We analyzed the incidence and risk factors of PTDM after renal transplantation, retrospectively. A total of 913 renal transplant recipients with normal glucose tolerance (NGT) were enrolled. The recipient who needs medical treatment of hyperglycemia more than one month was considered as PTDM patient. We classified PTDM as early PTDM (within post-Tx 1 year) and late PTDM. RESULTS: Two hundred seven cases of PTDM were developed (22.7%) out of 913 patients. The cumulative incidence of PTDM was 9.4%, 20.5% and 29.0% at post-transplantation 1-, 5- and 10 year respectively. In uni-variate and multivariate analysis of PTDM onset, elderly recipients, tacrolimus-based immunosuppressive group and hepatitis B virus carrier group showed significantly higher incidence of PTDM. Among 207 cases of PTDM, early and late PTDM were 85 cases and 122 cases respectively. The late PTDM developed persistently after post-transplant 5 years. In risk factor analysis of early and late PTDM, late PTDM showed different results compared to early PTDM. The clinical conditions that cause larger dose or high level of calcineurin inhibitor (CNI), such as double immunosuppressive regimen group, induction immunosuppressive therapy-free group and unrelated donor transplant group, were a significant independent risk factor of late PTDM. CONCLUSION: Our data showed clinical clues that persistent cumulative CNI exposure was correlated with onset of late PTDM. Careful selection of immunosuppressive regimen in high-risk recipients such as elderly patients and hepatitis B virus carrier may decrease the development of PTDM.
